Dissecting a post-translational modification code in cardiac reprogramming
剖析心脏重编程中的翻译后修饰代码
基本信息
- 批准号:10434240
- 负责人:
- 金额:$ 46.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-01 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AcetylationAnimal ModelAutomobile DrivingBindingCardiacCardiac MyocytesCell Differentiation processCell Fate ControlCellsChromatinCodeDevelopmentEnzymesEpigenetic ProcessEvolutionFibroblastsFoundationsGATA4 geneGene Expression RegulationGenetic TranscriptionHDAC4 geneHistone H3HistonesHumanInvestigationKnowledgeMediatingMethylationMolecularMusMyocardial InfarctionOutputPhosphoric Monoester HydrolasesPhosphorylationPhosphotransferasesPlayPost-Transcriptional RegulationPost-Translational Protein ProcessingProcessProtein Phosphatase 2A Regulatory Subunit PR53ProteinsRoleSystemTestingTherapeuticTranslatingWorkcardiac repairchromatin remodelingclinical applicationclinically relevantepigenetic regulationhistone modificationin vivoinsightmouse modelmyocyte-specific enhancer-binding-factor 2Cnovelorgan growthorgan regenerationpre-clinicalprogramstandem mass spectrometrytranscription factor
项目摘要
During development and evolution, cell fate changes are guided by cell’s ability to change its transcriptional
program with posttranslational modifications (PTMs) on both proteins and chromatin. PTMs of histones have
been extensively studied as a coding system to guide alterations in cell plasticity and cell fate, such as
differentiation/programming and de-differentiation/reprogramming. The histone PTM coding system includes
phosphorylation, acetylation, methylation, and ATP-dependent chromatin remodeling. In parallel, PTMs of free
proteins, such as phosphorylation and acetylation of transcription factors, are also essential for organ
development and cell differentiation. These PTMs in both histones and free proteins are often catalyzed by the
same set of epigenetic enzymes, strongly suggesting a dynamic interplay of PTM coding between histones and
epigenetic and transcription factors. However, few systematic studies have been pursued to define the
functional output of PTMs as a coding system. Furthermore, the potential synergistic effect of PTMs on both
histones and free factors in cell fate changes are poorly explored. Therefore, a deep understanding of the PTM
code on both free proteins (ie. key cardiac transcription factors and epigenetic factors) and histones and how
they work together will lead to novel insights into cell fate determination and cardiac reprogramming.
Our investigation of cardiac reprogramming uncovered a unique phosphorylation code in 14-3-3 binding
motifs (PC14-3-3). We hypothesize that activation of a phosphorylation code in 14-3-3 binding motifs triggers a
re-arrangement of protein-protein interactome among PC14-3-3 containing reprogramming factors, epigenetic
factors, and chromatin, which work synergistically in stimulating cardiac reprogramming. Specific aims:
Aim 1: Identify the key factors containing PC14-3-3 essential for cardiac reprogramming. We will test
the hypothesis that PC14-3-3 in key reprogramming, epigenetic and histone proteins plays a critical role in
reprogramming. These studies will build a knowledge foundation of PC14-3-3 in cardiac reprogramming.
Aim 2: Determine PC14-3-3 guided molecular mechanism in stimulating cardiac reprogramming. We
will test the hypothesis that PC14-3-3 activation triggers a protein-protein dynamic interplay among PC14-3-3
code containing reprogramming factors (Mef2c and Gata4), epigenetic factors (Hdac4 and Brg1), and histones
H3 (H3S10 and H3S28). These studies will establish PC14-3-3 directed epigenetic and chromatin landscape
changes in driving cardiac reprogramming.
Aim 3: Examine PC14-3-3-guided cardiac reprogramming toward therapeutic applications. We will
test the hypothesis that PC14-3-3 stimulates cardiac reprogramming in human cells and clinically relevant
animal models. These studies will establish the pre-clinical application of PC14-3-3 code in cardiac
reprogramming and build a novel and efficient platform for reprogramming-mediated heart repair.
在发育和进化过程中,细胞命运的改变是由细胞改变其转录水平的能力决定的
对蛋白质和染色质进行翻译后修饰(PTM)。组蛋白的PTM有
作为一种编码系统被广泛研究以指导细胞可塑性和细胞命运的改变,例如
分化/编程和去分化/重新编程。组蛋白PTM编码系统包括
磷酸化、乙酰化、甲基化和依赖于ATP的染色质重塑。同时,免费的PTMS
蛋白质,如转录因子的磷酸化和乙酰化,对器官也是必不可少的。
发育和细胞分化。组蛋白和游离蛋白中的这些PTM通常是由
相同的表观遗传酶,强烈表明组蛋白和组蛋白之间存在PTM编码的动态相互作用
表观遗传和转录因子。然而,很少有人进行系统的研究来定义
作为编码系统的PTMS的功能输出。此外,PTMS对两者的潜在协同效应
组蛋白和游离因子在细胞命运变化中的研究很少。因此,对PTM有深刻的认识
两种游离蛋白质上的密码(即关键的心脏转录因子和表观遗传因子)和组蛋白以及如何
他们的合作将导致对细胞命运决定和心脏重新编程的新见解。
我们对心脏重编程的研究发现了14-3-3结合的独特的磷酸化密码
图案(PC14-3-3)。我们假设14-3-3结合基序中的磷酸化代码的激活触发了
含有重编程因子的PC14-3-3之间的蛋白质-蛋白质相互作用组重排,表观遗传学
因子和染色质,它们在刺激心脏重编程方面协同工作。具体目标:
目的1:确定心脏重编程所必需的含有PC14-3-3的关键因子。我们将测试
假设PC14-3-3在关键的重编程、表观遗传和组蛋白蛋白中发挥关键作用
重新编程。这些研究将为PC14-3-3在心脏重编程中的应用奠定基础。
目的:探讨PC14-3-3在刺激心脏重编程中的分子机制。我们
将检验PC14-3-3激活触发PC14-3-3之间的蛋白质-蛋白质动态相互作用的假设
包含重编程因子(MEF2C和GATA4)、表观遗传因子(HDAC4和BRG1)和组蛋白的编码
H3(H3S10和H3S28)。这些研究将建立PC14-3-3导向的表观遗传和染色质景观
驱动心脏重编程的变化。
目的3:研究PC14-3-3引导下的心脏重编程治疗应用。我们会
验证PC14-3-3刺激人类细胞心脏重编程的假设及其临床意义
动物模型。这些研究将为PC14-3-3密码在心脏疾病中的临床前应用奠定基础。
重新编程,并为重新编程介导的心脏修复建立一个新颖而高效的平台。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zhong Wang其他文献
Zhong Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zhong Wang', 18)}}的其他基金
Dissecting a post-translational modification code in cardiac reprogramming
剖析心脏重编程中的翻译后修饰代码
- 批准号:
10599325 - 财政年份:2022
- 资助金额:
$ 46.55万 - 项目类别:
Nanofibrous self-gelling microspheres for heart regeneration
用于心脏再生的纳米纤维自凝胶微球
- 批准号:
10229376 - 财政年份:2019
- 资助金额:
$ 46.55万 - 项目类别:
Epigenetic control of multipotent cardiac progenitor cell differentiation
多能心脏祖细胞分化的表观遗传控制
- 批准号:
8448103 - 财政年份:2012
- 资助金额:
$ 46.55万 - 项目类别:
Epigenetic control of multipotent cardiac progenitor cell differentiation
多能心脏祖细胞分化的表观遗传控制
- 批准号:
8652492 - 财政年份:2012
- 资助金额:
$ 46.55万 - 项目类别:
Epigenetic control of multipotent cardiac progenitor cell differentiation
多能心脏祖细胞分化的表观遗传控制
- 批准号:
8297158 - 财政年份:2012
- 资助金额:
$ 46.55万 - 项目类别:
Nanomaterials Synthesis, Fabrication, and Characterization
纳米材料的合成、制造和表征
- 批准号:
7737197 - 财政年份:2008
- 资助金额:
$ 46.55万 - 项目类别:
Nanomaterials Synthesis, Fabrication, and Characterization
纳米材料的合成、制造和表征
- 批准号:
7937750 - 财政年份:
- 资助金额:
$ 46.55万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 46.55万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 46.55万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 46.55万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 46.55万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 46.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 46.55万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 46.55万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 46.55万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 46.55万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 46.55万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




